Lv7
4878 积分 2022-08-01 加入
Remarkable response after cocktail therapy with 177Lu-PSMA and 177Lu-DOTA-IBA in the treatment of mCRPC
12天前
已完结
[ 177 Lu]Lu-DOTATATE and [ 177 Lu]Lu-DOTA-IBA Cocktail Therapy for Metastatic Small Cell Lung Cancer: Possible Applications in Clinical Practice
12天前
已完结
ADC for SCLC Clears Phase I
13天前
已完结
SGO 2026 title page的pdf文件
23天前
已完结
Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization
24天前
已完结
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
1个月前
已完结
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck: A Multicenter, Phase IIa Trial
1个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
2个月前
已完结
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
2个月前
已完结
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer
3个月前
已完结
皖公网安备34019202002308
